Medtronic (MDT) Stock
Global medical device leader with diverse portfolio. Here's the price, business snapshot, and what's worth knowing about Medtronic in August 2026.
Medtronic PLC (MDT) is a leading global medical-technology company that designs, manufactures and sells a wide range of devices and therapies across cardiac, vascular, diabetes, neurological and spinal markets. Its portfolio includes pacemakers, insulin pumps, neurostimulation systems, spinal implants and surgical tools, generating a mix of implanted-device revenue and recurring consumables. With a market capitalisation of about $122.91bn, Medtronic benefits from ageing populations, steady demand for long-lived devices and an ongoing pipeline of incremental innovations. Important investor considerations include regulatory scrutiny, reimbursement and pricing pressures, competition from peers and emerging entrants, and occasional litigation. The company has historically returned cash through dividends and buybacks, but future payouts depend on cash flow and strategic priorities. This overview is general educational information only and not personalised investment advice; values can rise or fall and past performance is not a guarantee of future results.
Why It’s Moving
Medtronic stays in focus as dividend strength, regulatory wins, and looming earnings keep the stock moving.
- Medtronic announced a second-quarter fiscal 2027 cash dividend on August 20, reinforcing its reputation as a steady income name and signaling management’s confidence in cash generation.
- Investor attention is also building ahead of the company’s September 1 earnings report, with recent commentary suggesting the market is watching whether last quarter’s organic growth momentum can carry into the new fiscal year.
- Fresh regulatory progress for the Affera cardiac ablation platform, including a Health Canada approval earlier in the week, is supporting optimism around Medtronic’s heart rhythm franchise and its ability to drive growth beyond mature product lines.
Medtronic stays in focus as dividend strength, regulatory wins, and looming earnings keep the stock moving.
- Medtronic announced a second-quarter fiscal 2027 cash dividend on August 20, reinforcing its reputation as a steady income name and signaling management’s confidence in cash generation.
- Investor attention is also building ahead of the company’s September 1 earnings report, with recent commentary suggesting the market is watching whether last quarter’s organic growth momentum can carry into the new fiscal year.
- Fresh regulatory progress for the Affera cardiac ablation platform, including a Health Canada approval earlier in the week, is supporting optimism around Medtronic’s heart rhythm franchise and its ability to drive growth beyond mature product lines.
Sixth Month Growth Performance
next-earnings-question
The next Medtronic earnings date is expected on September 1, 2026. It will cover fiscal Q1 2027, which ended on July 31, 2026. This timing fits Medtronic’s typical late-August to early-September reporting pattern for its first fiscal quarter.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Medtronic's stock with a target price of $93.59, suggesting significant growth potential.
Financial Health
Medtronic is performing well with strong revenue and profits, indicating healthy business operations.
Dividend
Medtronic's dividend yield of 3.5% provides a reasonable return for investors seeking regular income. If you invested $1000, you would be paid $28.40 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Steady implant demand
Implanted devices and related consumables can provide recurring revenue as populations age, though demand and pricing may vary across markets.
Global market reach
Sales span developed and emerging markets, offering diversification but exposing the company to currency and local reimbursement risks.
R&D-driven pipeline
Ongoing product development and approvals can drive long-term growth, although clinical outcomes and commercial uptake are uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
